Breaking News

Genisphere Expands LIMR Pact

November 30, 2012

To develop nanotherapeutics targeting cancers and eye diseases

Genisphere and the Lankenau Institute for Medical Research (LIMR) have partnered to develop nanotherapeutics targeting cancers and eye diseases. This partnership expands an existing collaboration to identify inflammatory bowel disease biomarkers.
Genisphere will use its 3DNA dendrimer, which allows researchers to deliver a therapeutic agent to any target cell. It is manufactured from natural strands of DNA hybridized together to create high biocompatibility and low toxicity. With the dendrimer technology, LIMR researchers are using targeted drug delivery to treat ovarian, cervical, prostate and pancreatic cancer, as well as a therapy that uses small molecule drugs to target cells that cause post-cataract surgery eye lesions.
"LIMR is fortunate to partner with Genisphere for the development of its cancer nanotherapies,” said George Prendergast, Ph.D., president and chief executive officer of LIMR. “Given the wonderful intersection of these two organizations, we will have the right tools and skill sets to strengthen the path forward for clinical testing and ultimately commercialization."
“LIMR, with its team of talented scientists, is an ideal partner for us to study how certain therapeutics work with our DNA dendrimer nanoparticles,” said Bob Getts, chief science officer of Genisphere.

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent